RT Journal Article
SR Electronic
T1 HUMORAL AND CELLULAR IMMUNOGENICITY and SAFETY UP TO 4 MONTHS AFTER VACCINATION WITH BNT162B2 mRNA COVID-19 VACCINE IN HEART AND LUNG TRANSPLANTED YOUNG ADULTS
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.20.21263836
DO 10.1101/2021.09.20.21263836
A1 Cotugno, Nicola
A1 Pighi, Chiara
A1 Morrocchi, Elena
A1 Ruggiero, Alessandra
A1 Amodio, Donato
A1 Medri, Chiara
A1 Colagrossi, Luna
A1 Russo, Cristina
A1 Cesare, Silvia Di
A1 Santilli, Veronica
A1 Manno, Emma Concetta
A1 Zangari, Paola
A1 Giancotta, Carmela
A1 Bernardi, Stefania
A1 Nicolosi, Luciana
A1 Degli Atti, Marta Ciofi
A1 Raponi, Massimiliano
A1 Zaffina, Salvatore
A1 Alfieri, Sara
A1 Kirk, Richard
A1 Perno, Carlo Federico
A1 Rossi, Paolo
A1 CONVERS study Team
A1 Amodeo, Antonino
A1 Palma, Paolo
YR 2021
UL http://medrxiv.org/content/early/2021/09/22/2021.09.20.21263836.abstract
AB Background Immunizations among vulnerable population, including solid organ transplant recipients (SOT), present suboptimal responses at vaccination and over time. We investigated safety and immunogenicity of the BNT162B2 mRNA COVID-19 vaccine in 34 SOT young adults as compared to 36 healthy controls (HC).Methods immunogenicity was measured through the analysis of anti SARS-CoV2 IgG Antibodies and antigen specific CD4 T cells (CD40L+), detected by flow cytometry before vaccination, 21 days after priming (T21), 7 days after booster dose (T28) and 2-4 months after priming (T120). Baseline T and B cell immune phenotype was deeply investigated. The safety profile was investigated by close monitoring and self-reported diary.Results Anti-S and anti-Trimeric Ab responses were significantly lower in SOT vs HC at T21 (p<0.0001) and at T28 (p<0.0001). Ten out of 34 SOT (29%) at T28 and 3 out of 33 (9%) at T120 had undetectable SARS-CoV-2 IgG. The analysis of SARS-CoV-2 specific CD4 T cells showed lower CD40L expression after in vitro stimulation in SOT compared to HC. Lower frequencies of memory B cells were found in patients not responding to vaccination. Lack of seroconversion was higher in patients treated with mycophenolate (p=0.0005). The vaccination was safe and well tolerated. Only short-term adverse events, were reported and no hospitalization or graft rejection were observed after vaccinations.Conclusions These data show that SOT have a suboptimal immune response following mRNA vaccinations as compared to HC. Alternative strategies should be investigated to improve the immunization against SARS-CoV-2 in these patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was made possible by support from Bambino Gesu Children Hospital through Italian Ministry of Health, ricerca corrente 2020 to NC and ricerca corrente 2019 to PP.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Bambino Gesu' Children's Hospital Ethical CommitteeAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used for the submitted paper are available upon request to the Corresponding Author.Anti-HLAanti human leukocyte antigenCOVID19coronavirus disease 2019EDTAEthylenediamine tetraacetic acidHChealthy controlsIFNinterferonIL2interleukin 2mRNAmessenger Ribonucleic AcidPBMCsPeripheral Blood Mononuclear CellsSARS-CoV-2Severe Acute Respiratory Syndrome Coronavirus-2SOTSolid Organ Transplant Recipients